James N. Kochenderfer

Best Publications

• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

  Daniel W Lee;James N Kochenderfer;Maryalice Stetler-Stevenson;Yongzhi K Cui

  3247
  Citations

• Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

  James N. Kochenderfer;Mark E. Dudley;Sadik H. Kassim;Robert P.T. Somerville

  2096
  Citations

• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

  James N. Kochenderfer;Mark E. Dudley;Steven A. Feldman;Wyndham H. Wilson

  1741
  Citations

• Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

  Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  1708
  Citations

• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

  James N. Kochenderfer;Wyndham H. Wilson;John E. Janik;Mark E. Dudley

  1590
  Citations

• Toxicities of chimeric antigen receptor T cells: recognition and management.

  Jennifer N. Brudno;James N. Kochenderfer

  1415
  Citations

• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

  Jennifer N. Brudno;James N. Kochenderfer

  828
  Citations

• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

  Syed Abbas Ali;Victoria Shi;Irina Maric;Michael Wang

  822
  Citations

• T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

  Jennifer N. Brudno;Irina Maric;Steven D. Hartman;Jeremy J. Rose

  796
  Citations

• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

  Jennifer N. Brudno;Robert P.T. Somerville;Victoria Shi;Jeremy J. Rose

  759
  Citations

• B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

  Robert O. Carpenter;Moses O. Evbuomwan;Stefania Pittaluga;Jeremy J. Rose

  716
  Citations

• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  James N. Kochenderfer;Mark E. Dudley;Robert O. Carpenter;Sadik H. Kassim

  685
  Citations

• Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

  James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  593
  Citations

• Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

  James N. Kochenderfer;Steven A. Rosenberg

  574
  Citations

• Chimeric antigen receptor T-cell therapies for lymphoma

  Jennifer N Brudno;James N Kochenderfer

  518
  Citations

• Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

  James N. Kochenderfer;Steven A. Feldman;Yangbing Zhao;Hui Xu

  501
  Citations

• Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

  James N. Kochenderfer;Zhiya Yu;Dorina Frasheri;Nicholas P. Restifo

  437
  Citations

• Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

  Marianna Sabatino;Jinhui Hu;Michele Sommariva;Michele Sommariva;Sanjivan Gautam

  393
  Citations

• A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

  Yangbing Zhao;Qiong J. Wang;Shicheng Yang;James N. Kochenderfer

  388
  Citations

• A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

  Kathryn M Cappell;James N Kochenderfer

  348
  Citations